	US 12,435,084 B2
	Indazole derivatives as inhibitors of SARM1
Jonathan Bentley, Abingdon (GB); Shelley Anne Parrott, Abingdon (GB); Andrew Simon Brearley, Chilton (GB); Todd Bosanac, New Milford, CT (US); Robert Owen Hughes, Newtown, CT (US); and Rajesh Devraj, Chesterfield, MO (US)
Assigned to Eli Lilly and Company, Indianapolis, IN (US)
Appl. No. 17/995,046
Filed by Disarm Therapeutics, Inc., Cambridge, MA (US)
PCT Filed Apr. 7, 2021, PCT No. PCT/US2021/026102 § 371(c)(1), (2) Date Sep. 29, 2022, PCT Pub. No. WO2021/207302, PCT Pub. Date Oct. 14, 2021.
Claims priority of provisional application 63/007,773, filed on Apr. 9, 2020.
Prior Publication US 2023/0286978 A1, Sep. 14, 2023
Int. Cl. C07D 471/04 (2006.01); C07D 401/04 (2006.01); C07D 403/04 (2006.01); C07D 413/04 (2006.01); C07D 417/04 (2006.01)

CPC C07D 471/04 (2013.01) [C07D 401/04 (2013.01); C07D 403/04 (2013.01); C07D 413/04 (2013.01); C07D 417/04 (2013.01)]

10 Claims

1. A compound of Formula II:

or a pharmaceutically acceptable salt thereof, wherein:

R¹is a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein the 5- to 6-membered heteroaryl ring is optionally substituted with fluorine or methyl;

R²is a 5- to 6-membered heteroaryl ring having 1 heteroatom selected from nitrogen and sulfur, or phenyl, wherein the 5- to 6-membered heteroaryl ring or phenyl is optionally substituted with 1-2 groups selected from fluorine and chlorine;

R⁴is hydrogen or methyl;

Q is N;

X, Y and Z are independently CR⁵or a nitrogen atom, provided that no more than two X, Y and Z are nitrogen atoms; and

R⁵is hydrogen or methyl.